Moreover, targeting AKT-RICTOR signalling pathways by PI3K-inhibitors in combination with other forms of conventional (radio/chemo/stem cell transplant) treatments could overcome AML progression [45,46,47]. Here, AKT1 is linked to acute myeloid leukemia.